DOI: 10.17826/cumj.2001681 ISSN: 2602-3032

EZH2 expression in diffuse large B-cell lymphoma: clinicopathological associations and relationship with survival

Mehmet Mutlu Kıdı, Mehmet Türker, Sedat Biter, Melek Ergin, Tuğba Toyran, Tolga Köşeci, Hatice Asoğlu, Yasemin Aydınalp Camadan, İsmail Oğuz Kara, Berksoy Şahin, Ertuğrul Bayram
Show PDF Cite
Purpose: Enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator implicated in the pathogenesis of diffuse large B-cell lymphoma, but the prognostic value of its protein expression is uncertain. We evaluated EZH2 expression and its associations with clinicopathological features and survival.Materials and Methods: We retrospectively studied 50 patients with diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. EZH2 expression was assessed by immunohistochemistry using an H-score and classified as high (≥150) or low (

More from our Archive